A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
17 06 2021
Historique:
received: 04 09 2020
accepted: 11 02 2021
pubmed: 11 3 2021
medline: 15 12 2021
entrez: 10 3 2021
Statut: ppublish

Résumé

Leukemias bearing fusions of the AF10/MLLT10 gene are associated with poor prognosis, and therapies targeting these fusion proteins (FPs) are lacking. To understand mechanisms underlying AF10 fusion-mediated leukemogenesis, we generated inducible mouse models of acute myeloid leukemia (AML) driven by the most common AF10 FPs, PICALM/CALM-AF10 and KMT2A/MLL-AF10, and performed comprehensive characterization of the disease using transcriptomic, epigenomic, proteomic, and functional genomic approaches. Our studies provide a detailed map of gene networks and protein interactors associated with key AF10 fusions involved in leukemia. Specifically, we report that AF10 fusions activate a cascade of JAK/STAT-mediated inflammatory signaling through direct recruitment of JAK1 kinase. Inhibition of the JAK/STAT signaling by genetic Jak1 deletion or through pharmacological JAK/STAT inhibition elicited potent antioncogenic effects in mouse and human models of AF10 fusion AML. Collectively, our study identifies JAK1 as a tractable therapeutic target in AF10-rearranged leukemias.

Identifiants

pubmed: 33690798
pii: S0006-4971(21)00578-4
doi: 10.1182/blood.2020009023
pmc: PMC8212510
doi:

Substances chimiques

MLLT10 protein, human 0
Neoplasm Proteins 0
STAT Transcription Factors 0
Transcription Factors 0
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3403-3415

Subventions

Organisme : NCI NIH HHS
ID : P50 CA206963
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197594
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176745
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA154880
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA200643
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204639
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA066996
Pays : United States

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Blood. 2016 Oct 6;128(14):1845-1853
pubmed: 27531676
Leukemia. 2008 Apr;22(4):678-85
pubmed: 18094714
Genes Chromosomes Cancer. 1999 May;25(1):33-9
pubmed: 10221337
Leukemia. 2013 Dec;27(12):2419-21
pubmed: 23670296
Cell Stem Cell. 2017 Oct 5;21(4):489-501.e7
pubmed: 28965767
Nat Rev Rheumatol. 2017 Apr;13(4):234-243
pubmed: 28250461
Mol Ther Nucleic Acids. 2017 Mar 17;6:315-326
pubmed: 28325298
Annu Rev Pathol. 2012;7:283-301
pubmed: 22017583
Curr Opin Genet Dev. 2002 Feb;12(1):111-5
pubmed: 11790564
Blood. 2013 Jun 6;121(23):4758-68
pubmed: 23487024
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):119-21
pubmed: 17988908
Nat Rev Cancer. 2007 Nov;7(11):823-33
pubmed: 17957188
Blood. 2018 Jun 14;131(24):2661-2669
pubmed: 29724899
Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):47-51
pubmed: 25081372
Haematologica. 2006 Sep;91(9):1212-21
pubmed: 16956820
Cancer Genet Cytogenet. 2006 Sep;169(2):114-20
pubmed: 16938568
Cancer Cell. 2020 Apr 13;37(4):530-542
pubmed: 32289275
Leukemia. 2015 Feb;29(2):423-32
pubmed: 25027513
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30
pubmed: 31738426
Expert Opin Pharmacother. 2017 Dec;18(18):1929-1938
pubmed: 29134817
Blood. 2003 Aug 1;102(3):1000-6
pubmed: 12676784
Nat Commun. 2019 May 16;10(1):2198
pubmed: 31097696
Exp Hematol. 2014 Dec;42(12):1022-1030.e1
pubmed: 25193880
Nat Cell Biol. 2006 Sep;8(9):1017-24
pubmed: 16921363
Blood. 1998 Jun 15;91(12):4662-7
pubmed: 9616163
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366041
Exp Hematol. 2019 Jun;74:42-51.e3
pubmed: 31022428
Blood. 2013 Jun 20;121(25):5064-7
pubmed: 23673860
Blood. 2009 Sep 17;114(12):2489-96
pubmed: 19528532
Blood Cancer J. 2013 Jul 12;3:e124
pubmed: 23852159
Genes (Basel). 2020 Apr 15;11(4):
pubmed: 32326537
Br J Haematol. 2017 Jan;176(1):86-91
pubmed: 27766616
Br J Haematol. 2013 May;161(4):508-16
pubmed: 23480528
Br J Haematol. 2016 Aug;174(3):470-3
pubmed: 26455581
Blood Adv. 2019 Dec 23;3(24):4215-4227
pubmed: 31856268
Haematologica. 2014 May;99(5):64-6
pubmed: 24584351

Auteurs

Bo-Rui Chen (BR)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Anagha Deshpande (A)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Karina Barbosa (K)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Maria Kleppe (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Xue Lei (X)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Narayana Yeddula (N)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center and.

Pablo Sánchez Vela (PS)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Alexandre Rosa Campos (AR)

Proteomics Facility, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Robert J Wechsler-Reya (RJ)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Anindya Bagchi (A)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Soheil Meshinchi (S)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Connie Eaves (C)

Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.

Irmela Jeremias (I)

Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, German Center for Environmental Health, Munich, Germany.

Torsten Haferlach (T)

MLL Munich Leukemia Laboratory, Munich, Germany; and.

David A Frank (DA)

Department of Medical Oncology and.

Ze'ev Ronai (Z)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Sumit Chanda (S)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center and.

Scott A Armstrong (SA)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.

Peter D Adams (PD)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Ross L Levine (RL)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

Aniruddha J Deshpande (AJ)

Tumor Initiation and Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH